var title_f6_9_6288="Left ventricular tumor 4 chamber view";
var content_f6_9_6288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/50994/4chlvtum_conv.mp4?title=Left+ventricular+tumor+4+chamber+view\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intracardiac tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apical four-chamber view from a two-dimensional echocardiogram shows a tumor mass within the left ventricle, attached to the left ventricular wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6288=[""].join("\n");
var outline_f6_9_6288=null;
var title_f6_9_6289="Physeal fractures of the proximal humerus";
var content_f6_9_6289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Physeal fractures of the proximal humerus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) Salter-Harris I. Panel B) Salter-Harris II. Panel C) Salter-Harris III. Panel D) Salter-Harris IV.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sarwark JF, King EC, Luhmann SJ. Proximal humerus, scalpula, and clavicle. In: Rockwood and Wilkins' Fractures in Children, 6th edition, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6289=[""].join("\n");
var outline_f6_9_6289=null;
var title_f6_9_6290="Impetigo PI";
var content_f6_9_6290=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F59728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F59728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Impetigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When you have impetigo, your skin forms honey-colored crusts. It also turns red under the crusts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6290=[""].join("\n");
var outline_f6_9_6290=null;
var title_f6_9_6291="Spina bifida C";
var content_f6_9_6291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spina bifida and hydrocephaly (Arnold-Chiari) at 33 postmenstrual weeks and one day",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal view of the fetal head demonstrating the dilated posterior horns of the lateral ventricle in addition to the small cerebellum. The cisterna magna is not seen since the herniating cerebellum has obliterated it.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6291=[""].join("\n");
var outline_f6_9_6291=null;
var title_f6_9_6292="Incontinentia pigmenti 3";
var content_f6_9_6292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53297&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Incontinentia pigmenti",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Verrucous, hyperkeratotic linear plaques in a female infant with incontinentia pigmenti.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6292=[""].join("\n");
var outline_f6_9_6292=null;
var title_f6_9_6293="Naratriptan: Drug information";
var content_f6_9_6293=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naratriptan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/58/15269?source=see_link\">",
"    see \"Naratriptan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F199952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amerge&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F199953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amerge&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Naratriptan;",
"     </li>",
"     <li>",
"      Teva-Naratriptan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F199986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimigraine Agent;",
"     </li>",
"     <li>",
"      Serotonin 5-HT",
"      <sub>",
"       1B, 1D",
"      </sub>",
"      Receptor Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F199957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Migraine:",
"     </b>",
"     Oral: 1 mg to 2.5 mg at the onset of headache. It is recommended to use the lowest possible dose to minimize adverse effects. If headache returns or does not fully resolve, the dose may be repeated after 4 hours. Do not exceed 5 mg in 24 hours.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F199958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in the elderly.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F199959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate renal impairment: Initial: 1 mg; do not exceed 2.5 mg in 24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute): Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F199960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate hepatic impairment (Child-Pugh grade A or B): Initial: 1 mg; do not exceed 2.5 mg in 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe hepatic impairment (Child-Pugh grade C): Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F199933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg, 2.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amerge&reg;: 1 mg, 2.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F199921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do",
"     <b>",
"      not",
"     </b>",
"     crush or chew tablet; swallow whole with water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F199936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute migraine headache with or without aura",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F14308800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term prevention of menstrually-associated migraines (MAMs)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F199993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Amerge&reg; may be confused with Altace&reg;, Amaryl&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F199984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain/pressure (2% to 4%), malaise/fatigue (2%), dizziness (1% to 2%), drowsiness (1% to 2%), vertigo (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (4% to 5%), hyposalivation (1%), vomiting (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Photophobia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Ear/nose/throat infection (1%), pressure/tightness/heaviness sensations (1%), warm/cold temperature sensations (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal bilirubin tests, abnormal liver function tests, anaphylactoid reaction, anaphylaxis, anemia, bradycardia, cerebral infarction, colonic ischemia, coronary artery vasospasm, depression, dyspnea, ECG changes (atrial fibrillation, atrial flutter, premature ventricular contractions, PR prolongation, or QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation), eye hemorrhage, glycosuria, hallucinations, heart murmurs, hypercholesterolemia, hyperglycemia, hyper-/hypotension, hyperlipidemia, hypothyroidism, hypersensitivity reaction, ketonuria, MI, palpitation, panic, rash, seizure, serotonin syndrome, syncope, subarachnoid hemorrhage, thrombocytopenia, TIA, transient myocardial ischemia, ventricular fibrillation, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F199939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to naratriptan or any component of the formulation; cerebrovascular, peripheral vascular disease (ischemic bowel disease), ischemic heart disease (angina pectoris, history of myocardial infarction, or proven silent ischemia); or in patients with symptoms consistent with ischemic heart disease, coronary artery vasospasm, or Prinzmetal's angina; uncontrolled hypertension or patients who have received within 24 hours another 5-HT agonist (sumatriptan, zolmitriptan) or ergotamine-containing product; patients with known risk factors associated with coronary artery disease; patients with severe hepatic (Child-Pugh grade C) or renal disease (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute); do not administer naratriptan to patients with hemiplegic or basilar migraine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F199925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal's angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, such as dizziness, weakness, or drowsiness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasospasm-related events: Peripheral vascular ischemia and colonic ischemia have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery disease: Should not be given to patients who have risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) without adequate cardiac evaluation. Patients with suspected CAD should have cardiovascular evaluation to rule out CAD before considering use; if cardiovascular evaluation is &ldquo;satisfactory,&rdquo; first dose should be given in the healthcare provider's office (consider ECG monitoring).  Periodic evaluation of cardiovascular status should be done in all patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: In patients with mild-to-moderate hepatic impairment, naratriptan clearance is reduced ~30% and the elimination half-life is increased ~40%; dosage adjustment required in this patient population. Use is contraindicated in patients with severe hepatic impairment (Child-Pugh grade C).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: In patients with moderate renal impairment, naratriptan clearance is reduced ~50% and the elimination half-life is increased; dosage adjustment required in this patient population.  Use is contraindicated in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans) or agents which reduce naratriptan's metabolism. Concurrent use of serotonin precursors (eg, tryptophan) is not recommended.  If concomitant administration with SSRIs is warranted, monitor closely, especially at initiation and with dose increases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Only indicated for the acute treatment of migraine; not indicated for migraine prophylaxis, or for the treatment of cluster headache, hemiplegic or basilar migraine. Acute migraine agents (eg, triptans, opioids, ergotamine, or a combination of the agents) used for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse. If a patient does not respond to the first dose, the diagnosis of migraine should be reconsidered; rule out underlying neurologic disease in patients with atypical headache and in patients with no prior history of migraine. .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F199929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F199930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F199941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies using naratriptan in pregnant women. Use only if potential benefit to the mother outweighs the potential risk to the fetus. A pregnancy registry has been established to monitor outcomes of women exposed to naratriptan during pregnancy (800-336-2176). In animal studies, administration was associated with embryolethality, fetal abnormalities, and pup mortality and growth retardation. Tremors were observed in the offspring of female rats when exposed to naratriptan late in gestation.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F199963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F199940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Amerge Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (9): $343.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (9): $343.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Naratriptan HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (9): $265.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (9): $265.41",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F199942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antimigrin (AT);",
"     </li>",
"     <li>",
"      Naragran (DK);",
"     </li>",
"     <li>",
"      Naramig (AE, AR, AU, BE, BG, BH, BR, CH, CN, CO, CY, CZ, DE, EC, EE, EG, FI, FR, GB, GR, HU, IL, IQ, IR, JO, KP, KW, LB, LY, MX, NL, NO, NZ, OM, PE, PT, QA, RU, SA, SE, SG, SY, TH, TR, UY, YE);",
"     </li>",
"     <li>",
"      Naratrex (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F199924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective agonist for serotonin (5-HT",
"     <sub>",
"      1B",
"     </sub>",
"     and 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     receptors) in cranial arteries; causes vasoconstriction and reduces sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F199938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~1-2 hours (Bomhof, 1999; Tfelt-Hansen, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 170 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 28% to 31%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: 6 hours; increased in renal impairment (moderate impairment; mean: 11 hours; range: 7-20 hours); increased in hepatic impairment (moderate impairment: 8-16 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (50% of total dose as unchanged drug; 30% of total dose as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bomhof MK, Paz J, Legg N, et al, &ldquo;Comparison of Rizatriptan 10 mg vs Naratriptan 2.5 mg in Migraine,&rdquo;",
"      <i>",
"       Eur Neurol",
"      </i>",
"      1999, 42(3):173-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/9/6293/abstract-text/10529545/pubmed\" id=\"10529545\" target=\"_blank\">",
"        10529545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352:1112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/9/6293/abstract-text/15784664/pubmed\" id=\"15784664\" target=\"_blank\">",
"        15784664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silberstein SD, Holland S, Freitag F, et al, &ldquo;Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standard Subcommittee of the American Academy of Neurology and the American Headache Society,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 78(17):1337-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/9/6293/abstract-text/22529202/pubmed\" id=\"22529202\" target=\"_blank\">",
"        22529202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tfelt-Hansen P, de Vries P, Saxena PR, &ldquo;Triptans in Migraine: A Comparative Review of Pharmacology, Pharmacokinetics and Efficacy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2000, 60(6):1259-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/9/6293/abstract-text/11152011/pubmed\" id=\"11152011\" target=\"_blank\">",
"        11152011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10167 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6293=[""].join("\n");
var outline_f6_9_6293=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199952\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199953\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199986\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199957\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199958\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199959\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199960\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199933\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199921\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803174\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199936\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14308800\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199993\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199984\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199939\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199925\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299745\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199929\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199930\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199941\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199963\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199940\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199942\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199924\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199938\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10167\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10167|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/58/15269?source=related_link\">",
"      Naratriptan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_9_6294="Epidemiology and pathogenesis of gynecomastia";
var content_f6_9_6294=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and pathogenesis of gynecomastia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/9/6294/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/9/6294/contributors\">",
"     Glenn D Braunstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/9/6294/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/9/6294/contributors\">",
"     Alvin M Matsumoto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/9/6294/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/9/6294/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/9/6294/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecomastia, a benign proliferation of the glandular tissue of the male breast, is common in infancy, adolescence, and in middle-aged to elderly men. Pseudogynecomastia, which is often seen in obese men, refers to fat deposition without glandular proliferation. Gynecomastia must be differentiated from breast carcinoma, which is far less common.",
"   </p>",
"   <p>",
"    The epidemiology and pathogenesis will be reviewed here. The causes, evaluation, and management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=see_link\">",
"     \"Causes and evaluation of gynecomastia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/760?source=see_link\">",
"     \"Management of gynecomastia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecomastia is defined histologically as a benign proliferation of the glandular tissue of the male breast and clinically by the presence of a rubbery or firm mass extending concentrically from the nipple(s) (",
"    <a class=\"graphic graphic_figure graphicRef72334 \" href=\"UTD.htm?19/17/19730\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/9/6294/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Fat deposition without glandular proliferation is termed pseudogynecomastia and is often seen in obese men.",
"   </p>",
"   <p>",
"    The most important differentiation is between gynecomastia and breast carcinoma. Carcinoma is much less common, generally unilateral, eccentric in location rather than symmetrical to the nipple, hard or firm, and may be associated with skin dimpling, nipple retraction or discharge, and axillary lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/9/6294/abstract/3\">",
"     3",
"    </a>",
"    ]. Less common conditions leading to breast enlargement include neurofibromas, lymphangiomas, hematomas, lipomas, and dermoid cysts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecomastia is common in infancy, adolescence, and in middle-aged to elderly men. One estimate is that between 60 to 90 percent of infants have transient gynecomastia due to the high estrogenic milieu of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/9/6294/abstract/4\">",
"     4",
"    </a>",
"    ]. After delivery, the gynecomastia regresses in two to three weeks.",
"   </p>",
"   <p>",
"    The second peak is during puberty, with a prevalence ranging from 4 to 69 percent (",
"    <a class=\"graphic graphic_figure graphicRef64368 \" href=\"UTD.htm?23/42/24238\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/9/6294/abstract/5-12\">",
"     5-12",
"    </a>",
"    ]. This wide variation is probably due to differences in what is considered normal subareolar glandular tissue, observer differences, and probably most importantly, differences in the age distribution of the adolescents examined. Pubertal gynecomastia usually has an onset between ages 10 and 12 years and peaks between ages 13 and 14, usually at Tanner pubertal stage 3 or above (",
"    <a class=\"graphic graphic_table graphicRef76165 \" href=\"UTD.htm?31/46/32491\">",
"     table 1",
"    </a>",
"    ). It generally regresses within 18 months and persistence is uncommon after the age of 17.",
"   </p>",
"   <p>",
"    The third peak of gynecomastia occurs in middle-aged and elderly men. The highest prevalence is at 50 to 80 years, with as many as 24 to 65 percent of men being affected (",
"    <a class=\"graphic graphic_figure graphicRef64368 \" href=\"UTD.htm?23/42/24238\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/9/6294/abstract/13-18\">",
"     13-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although gynecomastia is usually bilateral, it is often asymmetrical and can even be unilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?6/9/6294/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In a study of 36 male patients who underwent subcutaneous mastectomy for a unilateral breast mass, 30 (83 percent) had gynecomastia, four (11 percent) had lipoma, and two had breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/9/6294/abstract/20\">",
"     20",
"    </a>",
"    ]. The majority of patients with gynecomastia were receiving medications known to cause gynecomastia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic mechanisms of gynecomastia include a decrease in androgen production, an increase in estrogen production, or increased availability of estrogen precursors for peripheral conversion to estrogen. Androgen receptor blockade and increased binding of androgen to sex-hormone binding globulin (SHBG) are other mechanisms.",
"   </p>",
"   <p>",
"    There does not appear to be any difference in the responsiveness of the male or female breast glandular tissue to hormonal stimulation. The amount of glandular proliferation and ductal differentiation depends upon an individual's breast tissue sensitivity, the hormonal milieu, and the duration and intensity of hormonal stimulation.",
"   </p>",
"   <p>",
"    Estrogens induce ductal epithelial hyperplasia, ductal elongation and branching, proliferation of the periductal fibroblasts, and an increase in vascularity. The histologic picture is similar in male and female breast tissue after exposure to estrogen. In comparison, luteal phase progesterone in women leads to acinar development that is not seen in males [",
"    <a class=\"abstract\" href=\"UTD.htm?6/9/6294/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The various conditions associated with gynecomastia are usually thought to represent an imbalance between the stimulatory effect of estrogen and the inhibitory effect of androgen (",
"    <a class=\"graphic graphic_figure graphicRef58706 \" href=\"UTD.htm?30/45/31454\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/9/6294/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The factors that define the net",
"    <span class=\"nowrap\">",
"     estrogen/androgen",
"    </span>",
"    balance are (",
"    <a class=\"graphic graphic_table graphicRef53166 \" href=\"UTD.htm?39/32/40459\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The production of these steroids or their precursors by the three steroid-producing tissues (the placenta, the adrenals, and the testes)",
"     </li>",
"     <li>",
"      The extraglandular conversion of androgens to estrogens, such as in adipose tissue",
"     </li>",
"     <li>",
"      The circulating concentration of sex-hormone binding globulin",
"     </li>",
"     <li>",
"      The hormone target cells' ability to respond to androgens and estrogens",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;During pregnancy the placenta transforms dehydroepiandrosterone and dehydroepiandrosterone sulfate (derived from both the mother and fetus) to estrone and estradiol, which enter the fetal circulation and stimulate breast glandular proliferation, resulting in transient neonatal gynecomastia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Estrogen in men",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adult men, 95 percent of the circulating testosterone, 15 percent of the estradiol (E2), and less than 5 percent of estrone (E1) is directly secreted by the testes (",
"    <a class=\"graphic graphic_figure graphicRef58706 \" href=\"UTD.htm?30/45/31454\">",
"     figure 3",
"    </a>",
"    ). The major androgen secreted by the adrenal glands is androstenedione. Most of the circulating estradiol and estrone are derived from the extraglandular conversion of testosterone and androstenedione to E2 and E1, respectively, by tissues including liver, skin, fat, muscle, bone and kidney, all of which contain an aromatase enzyme. There is also a substantial amount of interconversion between testosterone and androstenedione and between estradiol and estrone in extraglandular tissues via 17-hydroxysteroid dehydrogenase (17-ketosteroid reductase) enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?6/9/6294/abstract/21,24,25\">",
"     21,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sex hormone binding globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of androgens and estrogens that enter the circulation are relatively tightly bound to sex hormone binding globulin (SHBG) and are weakly bound to albumin. SHBG has a higher affinity for androgens than for estrogens and, therefore, any substance that displaces sex hormones from SHBG will tend to displace quantitatively more estrogens than androgens. The unbound or weakly bound androgens and estrogens enter the target cells and lead to hormone action [",
"    <a class=\"abstract\" href=\"UTD.htm?6/9/6294/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imbalance between estrogen and androgen",
"    </span>",
"    &nbsp;&mdash;&nbsp;An imbalance between estrogen and androgen action will occur if there is an absolute increase in free estrogens, a decrease in endogenous production of free androgens, an increase in the free estrogen-to-free androgen ratio, androgen insensitivity, or an estrogen-like effect of drugs (",
"    <a class=\"graphic graphic_figure graphicRef58706 \" href=\"UTD.htm?30/45/31454\">",
"     figure 3",
"    </a>",
"    ). Some patients with gynecomastia, for example, have enhanced sensitivity of the breast tissue to normal circulating estrogen levels even in the presence of normal circulating androgen concentrations. This may reflect increased aromatization of androgens to estrogens in the breast tissue itself, as increased aromatase activity has been found in pubic skin fibroblasts of patients with gynecomastia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/9/6294/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic studies show that the glandular changes in the breast are the same regardless of etiology, and the extent of glandular proliferation depends upon the intensity and duration of the stimulation. The histologic picture changes over time.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initially, there is extensive ductal epithelial hyperplasia, proliferation and lengthening of the ducts, an increase in the stromal and periductal connective tissue, and proliferation of periductal inflammatory cells. There is also extensive periductal edema and stromal fibroblastic proliferation. This is the early or florid stage of gynecomastia and generally is present for the first six months after onset and is associated with pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tenderness [",
"      <a class=\"abstract\" href=\"UTD.htm?6/9/6294/abstract/13,29-31\">",
"       13,29-31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After 12 or more months, the breast tissue evolves into the late or quiescent stage. At this time, there is a slight increase in the number of ducts, with marked dilatation of the ducts and little or no epithelial cell proliferation. There is also an increase in the amount of stroma, stromal fibrosis, and a disappearance of the inflammatory reaction. Pain and tenderness are uncommon during this stage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unlikely that any medical therapy will result in significant regression in the late fibrotic stage. As a result, medical therapies, if used, should be tried early in the course. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/760?source=see_link\">",
"     \"Management of gynecomastia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/30/44513?source=see_link\">",
"       \"Patient information: When men develop breasts (gynecomastia) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/47/41713?source=see_link\">",
"       \"Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gynecomastia is defined histologically as a benign proliferation of the glandular tissue of the male breast and clinically by the presence of a rubbery or firm mass extending concentrically from the nipple(s) (",
"    <a class=\"graphic graphic_figure graphicRef72334 \" href=\"UTD.htm?19/17/19730\">",
"     figure 1",
"    </a>",
"    ). Fat deposition without glandular proliferation is termed pseudogynecomastia (often seen in obese men). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gynecomastia is common in infancy and adolescence. It is estimated that between 60 to 90 percent of infants have transient gynecomastia due to the high estrogenic milieu of pregnancy. The second peak of occurrence is during puberty, affecting approximately 65 percent of boys. Spontaneous regression of breast tissue occurs in almost all cases. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The basic mechanisms of gynecomastia include a decrease in androgen production, an increase in estrogen production, or increased availability of estrogen precursors for peripheral conversion to estrogen. Androgen receptor blockade resulting in unopposed estrogen action is another mechanism. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The various conditions associated with gynecomastia are usually felt to represent an imbalance between the stimulatory effect of estrogen and the inhibitory effect of androgens. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histologic studies show that the glandular changes in the breast are the same regardless of etiology, and the extent of glandular proliferation depends upon the intensity and duration of the stimulation. The histologic picture changes over time, with early proliferation and inflammation, and later fibrosis. Medical therapy is unlikely to result in significant regression in the late fibrotic stage. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Histology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Braunstein GD. Pubertal gynecomastia. In: Pediatric Endocrinology, Lifshitz F (Ed), Marcel Dekker, New York 1996. p.197.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/2\">",
"      Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med 2007; 357:1229.",
"     </a>",
"    </li>",
"    <li>",
"     Moore MP. Male breast cancer. In: Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Hellman S (Eds), Lippincott-Raven, Philadelphia 1996. p.859.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/4\">",
"      Schmidt-Voigt, J. Brustdruenschwellungen bei mannlichen Jugendlichen des Pubertatsalters (Pubertatsmakromastie). Z Kinderheilkd 1941; 62:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/5\">",
"      Braunstein GD. Gynecomastia. N Engl J Med 1993; 328:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/6\">",
"      NYDICK M, BUSTOS J, DALE JH Jr, RAWSON RW. Gynecomastia in adolescent boys. JAMA 1961; 178:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/7\">",
"      Lee PA. The relationship of concentrations of serum hormones to pubertal gynecomastia. J Pediatr 1975; 86:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/8\">",
"      Fara GM, Del Corvo G, Bernuzzi S, et al. Epidemic of breast enlargement in an Italian school. Lancet 1979; 2:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/9\">",
"      Harlan WR, Grillo GP, Cornoni-Huntley J, Leaverton PE. Secondary sex characteristics of boys 12 to 17 years of age: the U.S. Health Examination Survey. J Pediatr 1979; 95:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/10\">",
"      Moore DC, Schlaepfer LV, Paunier L, Sizonenko PC. Hormonal changes during puberty: V. Transient pubertal gynecomastia: abnormal androgen-estrogen ratios. J Clin Endocrinol Metab 1984; 58:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/11\">",
"      Biro FM, Lucky AW, Huster GA, Morrison JA. Hormonal studies and physical maturation in adolescent gynecomastia. J Pediatr 1990; 116:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/12\">",
"      Kumanov P, Deepinder F, Robeva R, et al. Relationship of adolescent gynecomastia with varicocele and somatometric parameters: a cross-sectional study in 6200 healthy boys. J Adolesc Health 2007; 41:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/13\">",
"      WILLIAMS MJ. Gynecomastia. Its incidence, recognition and host characterization in 447 autopsy cases. Am J Med 1963; 34:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/14\">",
"      Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab 1979; 48:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/15\">",
"      Carlson HE. Gynecomastia. N Engl J Med 1980; 303:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/16\">",
"      Niewoehner CB, Nuttal FQ. Gynecomastia in a hospitalized male population. Am J Med 1984; 77:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/17\">",
"      Murray NP, Daly MJ. Gynaecomastia and heart failure--adverse drug reaction or disease process? J Clin Pharm Ther 1991; 16:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/18\">",
"      Georgiadis E, Papandreou L, Evangelopoulou C, et al. Incidence of gynaecomastia in 954 young males and its relationship to somatometric parameters. Ann Hum Biol 1994; 21:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/19\">",
"      O'Hanlon DM, Kent P, Kerin MJ, Given HF. Unilateral breast masses in men over 40: a diagnostic dilemma. Am J Surg 1995; 170:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/20\">",
"      Volpe CM, Raffetto JD, Collure DW, et al. Unilateral male breast masses: cancer risk and their evaluation and management. Am Surg 1999; 65:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/21\">",
"      Wilson JD, Aiman J, MacDonald PC. The pathogenesis of gynecomastia. Adv Intern Med 1980; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/22\">",
"      Rochefort H, Garcia M. The estrogenic and antiestrogenic activities of androgens in female target tissues. Pharmacol Ther 1983; 23:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/23\">",
"      Edmondson, HA, Glass, SJ, Soll, SN. Gynecomastia associated with cirrhosis of the liver. Proc Soc Exp Biol Med 1939; 42:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/24\">",
"      Smals AG. Gynaecomastia. Neth J Med 1987; 31:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/25\">",
"      Weinstein RL, Kelch RP, Jenner MR, et al. Secretion of unconjugated androgens and estrogens by the normal and abnormal human testis before and after human chorionic gonadotropin. J Clin Invest 1974; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/26\">",
"      Rose LI, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977; 87:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/27\">",
"      Grosso DS, Boyden TW, Pamenter RW, et al. Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins. Antimicrob Agents Chemother 1983; 23:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/28\">",
"      Bulard J, Mowszowicz I, Schaison G. Increased aromatase activity in pubic skin fibroblasts from patients with isolated gynecomastia. J Clin Endocrinol Metab 1987; 64:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/29\">",
"      Andersen JA, Gram JB. Gynecomasty: histological aspects in a surgical material. Acta Pathol Microbiol Immunol Scand A 1982; 90:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/30\">",
"      Nicolis GL, Modlinger RS, Gabrilove JL. A study of the histopathology of human gynecomastia. J Clin Endocrinol Metab 1971; 32:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/9/6294/abstract/31\">",
"      Bannayan GA, Hajdu SI. Gynecomastia: clinicopathologic study of 351 cases. Am J Clin Pathol 1972; 57:431.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7466 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6294=[""].join("\n");
var outline_f6_9_6294=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Estrogen in men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sex hormone binding globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imbalance between estrogen and androgen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7466\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7466|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/17/19730\" title=\"figure 1\">",
"      Exam for gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/42/24238\" title=\"figure 2\">",
"      Prevalence of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/45/31454\" title=\"figure 3\">",
"      Sex hormone production males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7466|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/46/32491\" title=\"table 1\">",
"      Tanner stages of male puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/32/40459\" title=\"table 2\">",
"      Pathophysiology gynecomastia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=related_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/760?source=related_link\">",
"      Management of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/47/41713?source=related_link\">",
"      Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/30/44513?source=related_link\">",
"      Patient information: When men develop breasts (gynecomastia) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_9_6295="Spread of sz by type";
var content_f6_9_6295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F76510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F76510&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Seizure types and potential routes of spread",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 461px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal brain sections depicting seizure types and potential routes of seizure spread.",
"    <strong>",
"     Panel A)",
"    </strong>",
"    Focal area of hyperexcitability (star under electrode 3) and spread to adjacent neocortex (solid arrow under electrode 4), via corpus callosum (dotted arrow) or other commissural pathways to the contralateral cerebral hemisphere, or via subcortical pathways (eg, thalamus, upward dashed arrows). Accompanying EEG patterns show brain electrical activity under electrodes 1-4. Focal epileptiform activity is maximal at electrode 3 and is also seen at electrode 4 (left traces). If a seizure secondarily generalizes, activity may be seen synchronously at all electrodes, after a delay (right traces).",
"    <strong>",
"     Panel B)",
"    </strong>",
"    A primary generalized seizure begins simultaneously in both hemispheres. The characteristic bilateral synchronous \"spike-wave\" pattern on EEG is generated by reciprocal interactions between the cortex and thalamus, with rapid spread via corpus callosum (CC) contributing to the rapid bilateral synchrony. One type of thalamic neuron (dark neuron) is a GABAergic inhibitory cell that displays intrinsic pacemaker activity. Cortical neurons (open triangles) send impulses to both thalamic relay neurons (open diamond) and to inhibitory neurons, setting up oscillations of excitatory and inhibitory activity, which gives rise to the rhythmic spike-waves on EEG.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stafstrom, CE. An introduction to seizures and epilepsy: cellular mechanisms underlying classification and treatment. In: Epilepsy and the Ketogenic Diet, Stafstrom, CE, Rho, JM (Eds), Humana Press, Totowa, New Jersey 2004. p.6. Copyright &copy; 2004 Springer-Verlag.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6295=[""].join("\n");
var outline_f6_9_6295=null;
var title_f6_9_6296="Hepatic VOD Reticulum";
var content_f6_9_6296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76089&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sinusoidal obstruction syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a reticulin stain of a liver biopsy from a patient with sinusoidal obstruction syndrome. There is prominent perivenular fibrosis (stained in black, arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced by permission from Negrin, RS, Blume, KG. Bone marrow and peripheral blood progenitor cell transplantation. In: Leukemia, 6th ed, Henderson, ES, Lister, TA, Greaves, ME (Eds), WB Saunders, Philadelphia, 1996, p. 389.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6296=[""].join("\n");
var outline_f6_9_6296=null;
var title_f6_9_6297="Moderate hidradenitis suppurativa";
var content_f6_9_6297=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65884%7EOBGYN%2F65188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65884%7EOBGYN%2F65188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Moderate hidradenitis suppurativa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe hidradenitis suppurativa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6297=[""].join("\n");
var outline_f6_9_6297=null;
var title_f6_9_6298="Ritonavir: Pediatric drug information";
var content_f6_9_6298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ritonavir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"    see \"Ritonavir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/35/5686?source=see_link\">",
"    see \"Ritonavir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Norvir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Norvir&reg;;",
"     </li>",
"     <li>",
"      Norvir&reg; SEC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Protease Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12864284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      HIV treatment:",
"     </b>",
"     Not approved for use; dose not established; further studies are needed;",
"     <b>",
"      Note:",
"     </b>",
"     Investigational dose of 450 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily resulted in lower ritonavir serum concentrations than those seen in adults receiving the standard adult dose.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      see \"Ritonavir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use in combination with other antiretroviral agents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ritonavir as sole protease inhibitor:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &gt;1 month and Children:",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended as the sole protease inhibitor in any regimen (DHHS [pediatric], 2011): Oral: Initial: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily (every 12 hours); titrate upward at 2-3 day intervals by 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily increments to 350-400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily; maximum dose: 600 mg/dose twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     Patients who do not tolerate 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily (due to adverse effects) may be treated with the highest tolerated dose; however, an alternative antiretroviral agent should be considered. Serum concentrations comparable to those seen in adults receiving standard doses were obtained in children &gt;2 years of age who received 350-400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily. In younger patients (1 month to 2 years of age), who received 350 or 450 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily, ritonavir AUCs were 16% lower and trough concentrations were 60% lower than those observed in adults receiving standard doses; higher ritonavir AUCs were not observed with the 450 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily compared to the 350 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose twice daily dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended as the primary protease inhibitor in any regimen (DHHS, 2011): 600 mg twice daily; may use a dose titration schedule to reduce adverse events (nausea/vomiting) by initiating therapy at 300 mg twice daily; increase dose at 2-3 day intervals by 100 mg twice daily increments up to a maximum dose of 600 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ritonavir as pharmacokinetic enhancer (&ldquo;booster doses&rdquo; of ritonavir):",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Ritonavir is used at lower doses to increase the serum concentrations of other protease inhibitors; the recommended dose of ritonavir varies when used with different protease inhibitors; see monographs for individual protease inhibitors for recommended doses; appropriate pediatric \"booster doses\" of ritonavir have not been established for use with every protease inhibitor or for all pediatric age groups.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Usual dose: 100-400 mg/day, usually as 100-200 mg once or twice daily; range: 100-800 mg/day; dose depends on the protease inhibitor (see",
"     <b>",
"      Note",
"     </b>",
"     above)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No adjustment recommended (renal clearance is negligible)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild to moderate hepatic impairment: No adjustment recommended; lower ritonavir serum concentrations have been reported in patients with moderate hepatic impairment (use with caution; monitor closely for adequate response)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment: Use with caution; pharmacokinetics of ritonavir has not been studied in these patients",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, soft gelatin, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norvir&reg;: 100 mg [contains ethanol, polyoxyl 35 castor oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norvir&reg;: 80 mg/mL (240 mL) [contains ethanol, polyoxyl 35 castor oil, propylene glycol; peppermint-caramel flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norvir&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals to improve tolerability. Swallow tablets whole; do not chew, break, or crush. Consider reserving liquid formulation for use in patients receiving tube feeding due to its bad taste. Shake liquid well before use. May mix liquid formulation with milk, chocolate milk, vanilla or chocolate pudding or ice cream, or a liquid nutritional supplement. Other techniques used to increase tolerance in children include dulling the taste buds by chewing ice, giving popsicles or spoonfuls of partially frozen orange or grape juice concentrates before administration of ritonavir; coating the mouth with peanut butter to eat before the dose; administration of strong-tasting foods such as maple syrup, cheese, or strong-flavored chewing gum immediately after a dose. Oral solution is highly concentrated; use a calibrated oral dosing syringe to measure and administer. Separate administration of ritonavir and didanosine by 2.5 hours.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsules: Refrigerate; stable for 30 days at room temperature &lt;77&deg;F (25&deg;C); protect from light; avoid exposure to excessive heat",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Dispense in original container or USP equivalent tight container (60 mL or less). Exposure to high humidity outside the original or USP equivalent tight container for &gt;2 weeks is",
"     <b>",
"      not",
"     </b>",
"     recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral solution: Dispense and store in original container; store at room temperature 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not refrigerate; avoid exposure to excessive heat; keep bottle tightly closed; use by product expiration date (limited shelf life of 6 months)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection in combination with other antiretroviral agents (FDA approved in ages &gt;1 month and adults).",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F218803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ritonavir may be confused with Retrovir&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Norvir&reg; may be confused with Norvasc&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F218801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Syncope, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, dizziness, fever, headache, insomnia, malaise, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia, triglycerides increased, uric acid increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, dyspepsia, flatulence, local throat irritation, nausea, taste perversion, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hepatic: GGT increased , transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, creatine phosphokinase increased, myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal vision. acute myeloblastic leukemia, adrenal cortex insufficiency, adrenal suppression, anaphylaxis, allergic reaction, amnesia, anemia, angioedema, aphasia, asthma, atrioventricular block (first, second, or third degree), bleeding increased (in patients with hemophilia A or B), bronchospasm, cachexia, cerebral ischemia, cerebral venous thrombosis, chest pain, cholestatic jaundice, coma, Cushing's syndrome, dehydration, dementia, depersonalization, diabetes mellitus, dyspnea, edema, esophageal ulcer, gastroenteritis, gastrointestinal hemorrhage, hallucinations, hepatic coma, hepatitis, hepatomegaly, hepatosplenomegaly, hyper-/hypotension, hypercholesteremia, hypothermia, hypoventilation, ileus, immune reconstitution syndrome, interstitial pneumonia, kidney failure, larynx edema, leukopenia, lymphadenopathy, lymphocytosis, manic reaction, MI, myeloproliferative disorder, neuropathy, orthostatic hypotension, palpitation, pancreatitis, paralysis, pseudomembranous colitis, QT prolongation, rectal hemorrhage, redistribution of body fat,right bundle branch block, seizure, skin melanoma, Stevens-Johnson syndrome, subdural hematoma, syncope, tachycardia, thrombocytopenia, tongue edema, torsade de pointes, toxic epidermal necrolysis, ulcerative colitis, urticaria, vasospasm",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis) to ritonavir or any component; concurrent therapy with alfuzosin, amiodarone, cisapride, dihydroergotamine, ergotamine, ergonovine, flecainide, lovastatin, methylergonovine, midazolam (oral), pimozide, propafenone, quinidine, sildenafil (when used for the treatment of pulmonary arterial hypertension), simvastatin, St John&rsquo;s wort, triazolam; concurrent therapy with voriconazole [when ritonavir dose is &ge;800 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     The &ge;800 mg/day is based on adult studies; the pediatric dose of ritonavir which requires voriconazole be contraindicated is not known; pediatric clinicians consider voriconazole to be contraindicated when using therapeutic doses of ritonavir; it should be noted that booster doses of ritonavir (in pediatric patients and adults) should be avoided in patients receiving voriconazole, unless benefit outweighs the risk]",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic insufficiency, elevated liver enzymes, or hepatitis. Ritonavir may prolong the PR interval; cases of second- or third-degree AV block have been reported; use with caution in patients with cardiomyopathy, ischemic heart disease, pre-existing conduction abnormalities, or structural heart disease [these patients may be at increased risk of conduction abnormalities (eg, second- or third-degree AV block)]; use with caution with drugs that prolong the PR interval. Spontaneous bleeding episodes have been reported in patients with hemophilia type A and B receiving protease inhibitors.  Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established). Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents, including ritonavir; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg, Grave&rsquo;s disease, Guillain-Barr&eacute; syndrome, and polymyositis) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Ritonavir oral solution contains 43% ethanol (v/v); accidental ingestion could result in alcohol-related toxicity. Patients converting dosage forms from the soft gel capsule to the tablet may experience more GI side effects due to higher peak serum concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ritonavir is a potent CYP3A enzyme inhibitor that interacts with numerous drugs",
"     <b>",
"      [U.S. Boxed Warnings]",
"     </b>",
"     . Due to potential serious and/or life-threatening drug interactions, some drugs are contraindicated. Concomitant use with fluticasone, salmeterol, high-dose ketoconazole, high-dose itraconazole, or high-dose or long-term use of meperidine is",
"     <b>",
"      not",
"     </b>",
"     recommended. Alteration of dose or serum concentration monitoring may be required with other medications. Use of ritonavir with other antiretroviral agents (eg, certain protease inhibitors) may require dosage adjustment of both agents (see individual monographs for specific dosage recommendations).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Potentially fatal pancreatitis may occur; advanced HIV disease and elevated serum triglycerides may place patient at increased risk; discontinue ritonavir in patients with pancreatitis. Hepatic reactions, including elevated liver enzymes, hepatitis, and jaundice may occur; coinfection with hepatitis B or C may increase risk; hepatic dysfunction with fatalities has also been reported. Significant elevations of serum triglycerides and cholesterol may occur (monitor and manage appropriately). Allergic reactions may also occur; discontinue ritonavir if severe allergic reaction occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     New onset diabetes mellitus, exacerbation of diabetes, and hyperglycemia have been reported in HIV-infected patients receiving protease inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F218789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C8 (strong), CYP2C9 (weak), CYP2D6 (strong), CYP2E1 (weak), CYP3A4 (strong), P-glycoprotein;",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (weak/moderate), CYP2C9 (weak/moderate), CYP3A4 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Protease Inhibitors may increase the serum concentration of ALPRAZolam.  Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: Ritonavir may decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Ritonavir may increase the serum concentration of Bosentan.  Management: Use bosentan 62.5 mg daily or every other day in adult patients who have been on ritonavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting ritonavir; wait until at least 10 days on ritonavir before restarting.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: Ritonavir may decrease the serum concentration of BuPROPion. Mixed effects on concentrations of the active hydroxybupropion metabolite have been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: Ritonavir may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clorazepate: Ritonavir may increase the serum concentration of Clorazepate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Protease Inhibitors may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Strong) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Ritonavir may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazepam: Ritonavir may increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May enhance the adverse/toxic effect of Ritonavir. This is specific for the lopinavir/ritonavir (Kaletra) oral solution due to its alcohol content (42%). Management: Concomitant use of Kaletra (lopinavir/ritonavir) oral solution and disulfiram should be avoided. Kaletra contains 42% alcohol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronabinol: Ritonavir may increase the serum concentration of Dronabinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May enhance the adverse/toxic effect of Ritonavir. Efavirenz may increase the serum concentration of Ritonavir. Ritonavir may increase the serum concentration of Efavirenz.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estazolam: Ritonavir may increase the serum concentration of Estazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Ritonavir may decrease the serum concentration of Etravirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Ritonavir may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flurazepam: Ritonavir may increase the serum concentration of Flurazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): Ritonavir may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Ritonavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Ritonavir may increase the serum concentration of Ketoconazole (Systemic).  Management: Limit the adult maximum ketoconazole dose to 200 mg/day in patients receiving ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Ritonavir may decrease the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: Ritonavir may increase the serum concentration of Linagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Protease Inhibitors may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Topical): May enhance the adverse/toxic effect of Ritonavir. A disulfiram-like reaction could occur due to the alcohol contained in Kaletra (lopinavir/ritonavir) oral solution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pioglitazone: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Pioglitazone.  Management: Limit pioglitazone adult maximum dose to 15 mg/day when used in combination with any strong CYP2C8 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Ritonavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PrednisoLONE (Systemic): Ritonavir may increase the serum concentration of PrednisoLONE (Systemic).  Management: Consider prednisolone dose reductions in patients receiving ritonavir and monitor for increased adverse effects with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PredniSONE: Ritonavir may increase the serum concentration of PredniSONE.  Management: Consider prednisone dose reductions in patients receiving ritonavir, and monitor for increased prednisone levels/adverse effects with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proguanil: Ritonavir may decrease the serum concentration of Proguanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Ritonavir may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of QuiNINE. This effect has been seen with lopinavir/ritonavir.  The individual contributions of lopinavir and ritonavir to this effect are unclear. Ritonavir may increase the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Ritonavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Ritonavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Ritonavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Ritonavir may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving ritonavir may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Ritonavir may decrease the serum concentration of Telaprevir. Ritonavir may increase the serum concentration of Telaprevir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inhibitors (Strong) may increase the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triamcinolone (Systemic): Ritonavir may enhance the adverse/toxic effect of Triamcinolone (Systemic). Specifically, risks of developing iatrogenic Cushing syndrome and secondary adrenal insufficiency may be increased. Ritonavir may increase the serum concentration of Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinBLAStine: Ritonavir may increase the serum concentration of VinBLAStine.  Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Ritonavir may increase the serum concentration of VinCRIStine.  Management: Monitor closely for signs and symptoms of vincristine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Ritonavir may decrease the serum concentration of Voriconazole.  Management: Concurrent voriconazole and high-dose ritonavir (adult doses of 400 mg every 12 hrs or greater) is contraindicated.  Voriconazole with lower-dose ritonavir should be avoided unless benefits outweigh risk of inadequate voriconazole concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Ritonavir may decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10114884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Food decreases peak concentrations by 23% and AUC by 7%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Food decreases the bioavailability of ritonavir tablets; however, no difference occurs between a high-fat meal versus a moderate-fat meal. A high fat meal decreases peak concentrations by 23% and AUC by 23%. A moderate-fat meal decreases peak concentrations by 22% and AUC by 21%.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F218743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies only with doses which were also maternally toxic. Ritonavir crosses the placenta in minimal amounts; no increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Early studies have shown lower plasma levels during pregnancy compared to postpartum. The DHHS Perinatal HIV Guidelines consider ritonavir to be a preferred protease inhibitor (PI) for use during pregnancy when used as a booster for other PIs. The oral solution contains alcohol and therefore may not be the best formulation for use in pregnancy. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and PIs should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with protease inhibitors; it is not clear if pregnancy increases this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, blood glucose concentrations, serum triglycerides, cholesterol, CPK, uric acid, CD4 cell count, plasma concentrations of HIV RNA",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A protease inhibitor which acts on an enzyme (protease) late in the HIV replication process after the virus has entered into the cell's nucleus; ritonavir binds to the protease activity site and inhibits the activity of the enzyme, thus preventing cleavage of viral polyprotein precursors (gag-pol protein precursors) into individual functional proteins found in infectious HIV; this results in the formation of immature, noninfectious viral particles",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: High concentrations in serum and lymph nodes; V",
"     <sub>",
"      d",
"     </sub>",
"     (apparent): 0.41 &plusmn; 0.25 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98% to 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver by cytochrome P450 isoenzyme CYP3A and (to a lesser extent) CYP2D6; five metabolites have been identified; the major metabolite (M-2), an isopropylthiazole oxidation metabolite, is active at a level similar to ritonavir, but is found in low concentrations in the plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Absolute bioavailability unknown; tablets are",
"     <b>",
"      not",
"     </b>",
"     bioequivalent to capsules; mean peak concentration of tablet was found to be 26% higher than capsule in a single dose study, in patients fed a moderate-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral solution: Fasting: 2 hours; nonfasting: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal clearance is negligible; 3.5% of dose is excreted as unchanged drug in the urine; 34% excreted as unchanged drug in the feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Pediatric patients: 1.5 to 1.7 times faster than adults",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/35/5686?source=see_link\">",
"      see \"Ritonavir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ritonavir is not a cure for HIV. Some medicines should not be taken with ritonavir; report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist; avoid the herbal medicine St John's wort. Take ritonavir every day as prescribed; do not change dose or discontinue without physician's advice; if dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do not double the next dose. Notify physician if you have an increase in thirst and/or frequent urination, nausea, vomiting, or abdominal pain, muscle numbness or tingling, respiratory difficulty or chest pain, unusual skin rash, change in color of stool or urine, or any persistent adverse effects.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Ritonavir may cause changes in the electrocardiogram (ECG); notify physician before starting ritonavir if you have a heart defect or conduction defect (these patients should avoid ritonavir); once taking ritonavir, notify physician if you develop lightheadedness, dizziness, an abnormal heart beat, or fainting spells. HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Patients taking the soft gel capsule may experience more GI side effects when switching to the tablet due to higher peak concentrations; these side effects may decrease as the medication is continued. Exposure of the tablets to high humidity outside the original container (or container given to you by the pharmacist) for longer than 2 weeks is",
"     <b>",
"      not",
"     </b>",
"     recommended.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Briars LA, Hilao JJ, and Kraus DM, &ldquo;A Review of Pediatric Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Journal of Pharmacy Practice",
"      </i>",
"      , 2004, 17(6):407-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Danner SA, Carr A, Leonard JM, et al, &ldquo;A Short-Term Study of the Safety, Pharmacokinetics, and Efficacy of Ritonavir, an Inhibitor of HIV-1 Protease. European-Australian Collaborative Ritonavir Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 333(23):1528-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/9/6298/abstract-text/7477167/pubmed\" id=\"7477167\" target=\"_blank\">",
"        7477167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSilva KE, Le Flore DB, Marston BJ, et al, &ldquo;Serotonin Syndrome in HIV-Infected Individuals Receiving Antiretroviral Therapy and Fluoxetine,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 2001, 15(10)1281-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/9/6298/abstract-text/11426073/pubmed\" id=\"11426073\" target=\"_blank\">",
"        11426073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" October 14, 2011, 1-167. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" August 11, 2011. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gatti G, Pontali E, Boni S, et al, &ldquo;The Relationship Between Ritonavir Plasma Trough Concentration and Virological and Immunological Response in HIV-Infected Children,&rdquo;",
"      <i>",
"       HIV Med",
"      </i>",
"      , 2002, 3(2):125-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/9/6298/abstract-text/12010359/pubmed\" id=\"12010359\" target=\"_blank\">",
"        12010359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mueller BU, Nelson RP Jr, Sleasman J, et al, &ldquo;A Phase I/II Study of the Protease Inhibitor Ritonavir in Children With Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 101(3 Pt 1):335-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/9/6298/abstract-text/9480994/pubmed\" id=\"9480994\" target=\"_blank\">",
"        9480994",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nachman SA, Lindsey JC, Pelton S, et al, &ldquo;Growth in Human Immunodeficiency Virus-Infected Children Receiving Ritonavir-Containing Antiretroviral Therapy,&rdquo;",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2002, 156(5):497-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/9/6298/abstract-text/11980557/pubmed\" id=\"11980557\" target=\"_blank\">",
"        11980557",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nachman SA, Stanley K, Yogev R, et al, &ldquo;Nucleoside Analogs Plus Ritonavir in Stable Antiretroviral Therapy-Experienced HIV-Infected Children: A Randomized Controlled Trial. Pediatric AIDS Clinical Trials Group 338 Study Team,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2000, 283(4):492-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/9/6298/abstract-text/10659875/pubmed\" id=\"10659875\" target=\"_blank\">",
"        10659875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12970 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6298=[""].join("\n");
var outline_f6_9_6298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709403\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218758\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218759\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055325\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12864284\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055317\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218733\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218718\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055329\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055320\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055328\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218803\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218801\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055332\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055316\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055315\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218789\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218727\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10114884\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218729\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218743\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055324\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055314\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055331\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055322\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12970\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12970|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=related_link\">",
"      Ritonavir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/35/5686?source=related_link\">",
"      Ritonavir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_9_6299="Antiarrhythmics and energy";
var content_f6_9_6299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=15\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=15\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The effect of antiarrhythmic agents on cardioversion energy requirements",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antiarrhythmic agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Energy requirement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lidocane",
"       </td>",
"       <td>",
"        Increased or no change",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quinidine",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phenytoin",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amiodarone",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flecainide",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ibutilide",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6299=[""].join("\n");
var outline_f6_9_6299=null;
var title_f6_9_6300="Causes of neonatal polycythemia";
var content_f6_9_6300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F85757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F85757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of neonatal polycythemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Erythrocyte transfusion (passive)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delayed clamping of the umbilical cord (eg, &gt;2 minutes after birth)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled or precipitous delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intrapartum hypoxia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Twin-to-twin transfusion (10 to 15 percent of monochorionic twins)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal-fetal transfusion (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Increased intrauterine erythropoiesis (active)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Placental insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Preeclampsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other hypertensive disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other vascular disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Maternal hypoxemia due to cardiac or pulmonary disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cardiac or pulmonary disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Drugs (eg, propranolol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        High altitude",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Post term delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Infant risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Large for gestational age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Maternal diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Beckwith-Wiedemann syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Endocrine abnormalities (congenital adrenal hyperplasia, hypothyroidism, hyperthyroidism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chromosomal anomalies (trisomy 21, 18, and 13)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Garcia-Prats.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6300=[""].join("\n");
var outline_f6_9_6300=null;
var title_f6_9_6301="Drug therapy NAS";
var content_f6_9_6301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F85854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F85854&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug therapy for neonatal abstinence syndrome (NAS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"5\">",
"            Initial opioid therapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2\">",
"            Drug",
"           </td>",
"           <td class=\"subtitle2\">",
"            Initial dose",
"           </td>",
"           <td class=\"subtitle2\">",
"            Incremental increase based on symptoms",
"           </td>",
"           <td class=\"subtitle2\">",
"            Maximum dose",
"           </td>",
"           <td class=\"subtitle2\">",
"            Weaning based on abstinence scoring",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Morphine",
"           </td>",
"           <td>",
"            <p>",
"             0.04 mg/kg every three to four hours given orally",
"            </p>",
"            <p>",
"             Oral dose should be given with feeds",
"            </p>",
"           </td>",
"           <td>",
"            0.04 mg/kg per dose",
"           </td>",
"           <td>",
"            0.2 mg/kg per dose",
"           </td>",
"           <td>",
"            <p>",
"             Taper dose by 10 to 20 percent every two to three days",
"            </p>",
"            <p>",
"             Discontinue morphine when the dose is weaned to 0.04 mg/kg per day without any increase in abstinence scores",
"            </p>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methadone",
"           </td>",
"           <td>",
"            0.05 to 0.1 mg/kg every six hours given orally",
"           </td>",
"           <td>",
"            0.05 mg/kg per dose",
"           </td>",
"           <td>",
"            To effect",
"           </td>",
"           <td>",
"            <p>",
"             Taper dose by 10 to 20 percent per week",
"            </p>",
"            <p>",
"             Discontinue when a dose of 0.05 mg/kg per day is reached",
"            </p>",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"5\">",
"            Phenobarbital used in combination with opioid therapy for infants with severe NAS or with multidrug exposure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2\">",
"            &nbsp;",
"           </td>",
"           <td class=\"subtitle2\">",
"            Loading dose",
"           </td>",
"           <td class=\"subtitle2\">",
"            Maintenance dose",
"           </td>",
"           <td class=\"subtitle2\">",
"            Therapeutic plasma goal",
"           </td>",
"           <td class=\"subtitle2\">",
"            Weaning",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <strong>",
"             Phenobarbital",
"            </strong>",
"           </td>",
"           <td>",
"            <p>",
"             Single loading dose of 15 to 20 mg/kg given orally, intravenously or intramuscularly.&nbsp;If symptoms are still severe 8 to 12 hours after initial&nbsp;dose, the dose can be repeated once (total cumulative maximum loading of 40 mg/kg).",
"            </p>",
"           </td>",
"           <td>",
"            <p>",
"             3 to 4 mg/kg per day started 12 to 24 hours after initial dose",
"            </p>",
"            <p>",
"             Administered as a single dose in the evening OR two divided doses given every 12 hours",
"            </p>",
"            <p>",
"             Increase dose by 1 to 5 mg/kg per day until therapeutic plasma levels are achieved",
"            </p>",
"           </td>",
"           <td>",
"            Therapeutic goal of trough plasma concentration level between 20 and 30 mg/dL (86 and 129 micromoles/L), obtained 24 to 48 hours after initiation or change in dosing",
"           </td>",
"           <td>",
"            <p>",
"             Phenobarbital should be weaned after morphine&nbsp;is fully tapered off",
"            </p>",
"            <p>",
"             Taper phenobarbital dose to decrease drug concentration by 10 to 20 percent per day",
"            </p>",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Hudak ML, et al. Neonatal drug withdrawal. Pediatrics 2012; 129:e540.",
"      </li>",
"      <li>",
"       Bio LL, Siu A, Poon CY. Update on the pharmacologic management of neonatal abstinence syndrome. J Perinatol 2011; 31:692.",
"      </li>",
"      <li>",
"       Tran JH. Treatment of neonatal abstinence syndrome. J Pediatr Health Care 1999; 13:295.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6301=[""].join("\n");
var outline_f6_9_6301=null;
var title_f6_9_6302="TG LDL HDL and coronary risk";
var content_f6_9_6302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Hypertriglyceridemia as a risk factor for coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 301px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from the Helsinki Heart Study, a randomized primary prevention trial in dyslipidemic men, showing the incidence of coronary events at five years according to the baseline serum triglyceride concentration and the LDL-to-HDL cholesterol ratio. The risk was markedly increased in patients with both a triglyceride concentration above 2.3 mmol/L [200 mg/dL]) and an elevated LDL-to-HDL ratio. A beneficial effect of gemfibrozil to lower the incidence of coronary events was limited to this group.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Manninen, V, Tenkanen, L, Koskinen, P, et al, Circulation 1992; 85:37.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6302=[""].join("\n");
var outline_f6_9_6302=null;
var title_f6_9_6303="Nipple retraction";
var content_f6_9_6303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F75440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F75440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nipple retraction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nipple retraction occurs when only a part of the nipple is drawn in because it is tethered by a single duct, resulting in a slit-like appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_9_6303=[""].join("\n");
var outline_f6_9_6303=null;
